Previous close | 1,377.50 |
Open | 1,374.50 |
Bid | 1,300.00 x 240300 |
Ask | 1,450.00 x 53000 |
Day's range | 1,361.00 - 1,378.50 |
52-week range | 1,173.00 - 1,442.00 |
Volume | 1,959,414 |
Avg. volume | 3,457,307 |
Market cap | 11.92B |
Beta | 0.21 |
PE ratio (TTM) | 15.56 |
EPS (TTM) | 87.70 |
Earnings date | 8 Feb 2018 - 13 Feb 2018 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.99 |
These two FTSE 100 (INDEXFTSE: UKX) shares could offer growth at a reasonable price.
A little known private-equity executive will steer WPP PLC through one of its stormiest periods following the resignation last weekend of Martin Sorrell.
Edward Sheldon identifies two FTSE 100 (INDEXFTSE: UKX) stocks that might be ideal investments for those in their 40s.
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market ...
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market ...
Despite its record of dividend growth, I believe this FTSE 100 (INDEXFTSE: UKX) income champion has a bleak outlook.
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market ...
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market ...
Artificial hip and knee maker Smith & Nephew (SN.L), a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott (ABT.N) in 2017. The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.
Artificial hip and knee maker Smith & Nephew (Frankfurt: 502816 - news) , a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere (NYSE: ALR - news) , where he oversaw its $5.3 billion sale to Abbott in 2017.
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market ...
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market ...
Artificial hip and knee maker Smith & Nephew said on Wednesday it had appointed Namal Nawana to replace Olivier Bohuon as chief executive of the British company next month. Nawana was most recently chief ...
The FTSE-100 medical devices group Smith & Nephew (Frankfurt: 502816 - news) (S&N) will this week end its six-month search for a new boss by naming a former Alere (NYSE: ALR - news) executive to the role. Sky News has learnt that S&N will announce on Wednesday that Namal Nawana will join the global leader in orthopaedics reconstruction in the coming months. Mr Nawana, a 46-year-old Australian citizen, will replace Olivier Bohuon, who told the medical technology group's board last October that he intended to step down this year.
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
These two outstanding FTSE 100 (INDEXFTSE: UKX) firms are well worth your research time right now.
By Helen Reid LONDON (Reuters) - A takeover offer for NEX Group sent its shares shooting up by almost a third on Friday, while the FTSE 100 registered a weekly decline in spite of a boost from energy and ...
The FTSE 100 (INDEXFTSE: UKX) is packed with growth stocks that can make investors a fortune. Here are two such shares, including one making lots of headlines right now.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
LONDON--(BUSINESSWIRE)-- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces the publication of a randomised controlled trial (RCT) demonstrating that the addition ...
Smith & Nephew plc , the global medical technology business, today announces the publication of a randomised controlled trial demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew’s leading multi-layer silicone adhesive foam dressing, to a standard care protocol significantly reduces the onset of pressure ulcers by 71% in elderly patients admitted to hospital for hip fracture1.
Artificial hip and knee maker Smith & Nephew scraped into the bottom of its guidance range for 2017, with a 3 percent rise in revenue to $4.77 billion pounds and a 20 basis point increase in its trading ...